An Innovative Local Radiotherapeutic Treatment with Potential for Systemic Effect
Alpha DaRT ® is uniquely designed to target localized tumor destruction with potential systemic immune activation—positioning it as a differentiated radiotherapeutic across multiple solid tumor types.

Rapidly Advancing Clinical and Regulatory Progress
With clinical trials across multiple tumor types already underway, and an expanding U.S. clinical trial footprint, Alpha Tau is advancing efficiently on a global regulatory path.

Advancing Toward Strategic Commercial Readiness
Alpha Tau is building out manufacturing capabilities, exploring bold strategic partnerships, and prioritizing attractive commercial markets to achieve efficient and scalable go-to-market execution.